+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P00249(CCL25 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P00249(CCL25 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

CCL25. also known as thymus-expressed chemokine (TECK), is a small chemotactic cytokine belonging to the CC chemokine subfamily. It is primarily produced by thymic dendritic cells and intestinal epithelial cells, playing a crucial role in immune cell trafficking and tissue-specific immunity. CCL25 selectively binds to the CCR9 receptor, which is prominently expressed on immune cells like T lymphocytes, dendritic cells, and gut-homing leukocytes. This ligand-receptor interaction is essential for directing immune cell migration to the thymus and gastrointestinal tract, influencing T-cell development, mucosal immunity, and inflammatory responses.

CCL25 antibodies are vital research tools for detecting and modulating CCL25 activity in experimental settings. They enable the study of CCL25 expression patterns in diseases such as inflammatory bowel disease (IBD), celiac disease, and colorectal cancer, where dysregulated CCL25/CCR9 signaling is implicated. In therapeutic contexts, neutralizing CCL25 antibodies are explored for their potential to inhibit pathogenic immune cell infiltration in autoimmune disorders or block cancer metastasis driven by CCR9-expressing tumor cells. These antibodies are widely used in techniques like flow cytometry, immunohistochemistry, and functional assays to dissect CCL25's role in immune regulation and tissue homeostasis. The development of CCL25-targeted therapies highlights its significance as a biomarker and intervention point in mucosal immunity and cancer research.